Evidence map›Paper›PMID 38481873›Full record

ArticleTranslational andrology and urology2024

Combination clomiphene citrate and anastrozole duotherapy improves semen parameters in a multi-institutional, retrospective cohort of infertile men.

Vadim Osadchiy, Carlos Munoz-Lopez, Tommy Jiang, Bryan D Naelitz, Neel Parekh, Sarah C Vij, Jesse N Mills, Scott D Lundy, Sriram V Eleswarapu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Vadim OsadchiyDivision of Andrology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Carlos Munoz-LopezDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Tommy JiangDivision of Andrology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Bryan D NaelitzDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Neel ParekhDivision of Andrology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Sarah C VijDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Jesse N MillsDivision of Andrology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Scott D LundyDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Sriram V EleswarapuDivision of Andrology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In men with impaired semen parameters, empiric medical therapies such as clomiphene citrate, a selective estrogen receptor modulator (SERM), and anastrozole, a selective aromatase inhibitor, are often employed. The effects of jointly administering these agents on semen parameters are not well understood. Here, we describe the findings of our multi-center, retrospective cohort study of men with idiopathic primary or secondary infertility. Twenty-one men were treated with combination therapy (anastrozole and clomiphene) and 69 men were treated with monotherapy (anastrozole). Patients with pre-treatment normozoospermia and recent or current exogenous testosterone therapy were excluded. Baseline and post-treatment semen and sex hormone parameters were compared among groups. The median follow-up duration was 91 days [interquartile range (IQR), 64-117 days]. Following treatment, 43% of men in the combination therapy group demonstrated normozoospermia, compared to 25% in the monotherapy group. Furthermore, men in the combined group demonstrated marked improvements in total motile sperm count (TMSC) [11.3

Indexed as

anastrozoleClomipheneidiopathic infertilitysemen analysis parameters (SA parameters)total motile sperm count (TMSC)

Identifiers

PMID38481873
PMCPMC10932640
OpenAlexW4392194091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.